Search for Clinical Trial Results
Adenoma, Islet Cell - 110 Studies Found
Status | Study |
Recruiting |
Study Name: Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Condition: Pancreatic Neuroendocrine Tumours. Date: 2014-08-20 Interventions:
|
Completed |
Study Name: Comparative Study of Robotic, Laparoscopic and Open Surgery for Enucleation of Benign Pancreatic Neoplasms Condition: Pancreatic Neuroendocrine Tumors Date: 2014-04-26 Interventions:
|
Enrolling by invitation |
Study Name: Gastroenteral-Pancreatic Neuroendocrine Tumors in Taiwan Condition: This Study Plans to Include 600 GEP-NET Patients. Date: 2014-02-27 |
Active, not recruiting |
Study Name: EUS-guided Ethanol-lipiodol Ablation of Pancreatic Neuroendocrine Tumor: a Prospective Study Condition:
Date: 2013-07-15 Interventions: Procedure: EUS-guided ethanol-lipiodol mixture ablation By using 3D-volumetric analysis, the optimal vol |
Completed |
Study Name: Chemotherapy Plus Endostatin in Advanced Pancreatic Neuroendocrine Tumor Condition: Advanced Well-differentiated Pancreatic Neuroendocrine Tumor Date: 2013-04-29 Interventions: Drug: temozolomide or dacarbazine-based chemotherapy, endostatin |
Completed |
Study Name: 68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours Condition: Neuroendocrine Tumours Date: 2012-08-09 Interventions: Drug: Diagnostic work up Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve |
Completed |
Study Name: BEZ235 Phase II Trial in Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET) After Failure of mTOR Inhibitor Therapy. Condition: Pancreatic Neuroendocrine Tumors (pNET) Date: 2012-07-06 Interventions: Drug: BEZ235 (Stage 1) The investigational study drug used in this trial was BEZ235, which was supplied |
Terminated |
Study Name: Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Tumors (pNET) Date: 2012-06-25 Interventions:
|
Recruiting |
Study Name: Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors Condition: Pancreatic Neuroendocrine Cancer Date: 2012-05-16 Interventions: Other: MRI Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy accor |
Active, not recruiting |
Study Name: A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors Condition: Well-differentiated Pancreatic Neuroendocrine Tumor Date: 2012-01-13 Interventions: Drug: sunitinib Sunitinib capsules will be given orally at continuous daily dosing with a starting dose |